Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Tag: Naegleria fowleri

Naegleria fowleri: Protein structures to facilitate drug discovery for the deadly, pathogenic free-living amoeba

Naegleria fowleri is a pathogenic, thermophilic, free-living amoeba which causes primary amebic meningoencephalitis (PAM). Penetrating the olfactory mucosa, the brain-eating amoeba travels along the olfactory nerves, burrowing through the cribriform plate to its destination: the brain’s frontal lobes. The amoeba thrives in warm, freshwater environments, with peak infection rates in the summer months and has a mortality rate of approximately 97%. A major contributor to the pathogen’s high mortality is the lack of sensitivity of N. fowleri to current drug therapies, even in the face of combination-drug therapy. To enable rational drug discovery and design efforts we have pursued protein production and crystallography-based structure determination efforts for likely drug targets from N. fowleri. The genes were selected if they had homology to drug targets listed in Drug Bank or were nominated by primary investigators engaged in N. fowleri research. In 2017, 178 N. fowleri protein targets were queued to the Seattle Structural Genomics Center of Infectious Disease (SSGCID) pipeline, and to date 89 soluble recombinant proteins and 19 unique target structures have been produced. Many of the new protein structures are potential drug targets and contain structural differences compared to their human homologs, which could allow for the development of pathogen-specific inhibitors. Five of the structures were analyzed in more detail, and four of five show promise that selective inhibitors of the active site could be found. The 19 solved crystal structures build a foundation for future work in combating this devastating disease by encouraging further investigation to stimulate drug discovery for this neglected pathogen.

Logan Tillery, Kayleigh Barrett, Jenna Goldstein, Jared W Lassner, Bram Osterhout, Nathan L Tran, Lily Xu, Ryan M Young, Justin Craig, Ian Chun, David M Dranow, Jan Abendroth, Silvia L Delker, Douglas R Davies, Stephen J Mayclin, Brandy Calhoun, Madison J Bolejack, Bart Staker, Sandhya Subramanian, Isabelle Phan, Donald D Lorimer, Peter J Myler, Thomas E Edwards, Dennis E Kyle, Christopher A Rice, James C Morris, James W Leahy, Roman Manetsch, Lynn K Barrett, Craig L Smith, Wesley C Van Voorhis (2021) Naegleria fowleri: Protein structures to facilitate drug discovery for the deadly, pathogenic free-living amoeba. PLoS ONE 16(3): e0241738. https://doi.org/10.1371/journal.pone.0241738

Trainee Spotlight: Beatrice Colon

trainee Beatrice Colon

Beatrice Colon, an Illinois native, is a Ph.D. trainee in Dennis Kyle’s laboratory. She holds a Bachelor of Science degree from the University of Illinois at Urbana-Champaign and a Master of Science degree from the University of South Florida (USF). She began her Ph.D. at USF as well.

Beatrice moved to the University of Georgia in January 2017 with the Kyle Lab.

“I decided to transfer universities because of the excellent infectious disease department,” said Beatrice.

Research and Training

“My favorite thing about the CTEGD is the openness for collaborations; the center is also very focused on training a new generation of scientists. “

Beatrice is currently working on a drug discovery project for the brain-eating amoeba, Naegleria fowleri. The disease was the major factor that drew her to the project. Primary amoebic meningoencephalitis is nearly always fatal and affects young healthy children. Moreover, there is not an effective drug treatment for people that do get infected with the amoeba.

In her short time at UGA, Beatrice has won first place for a poster presentation at the graduate student and postdoc symposium. She was also selected for the Biology of Parasitism course at Woods Hole, MA this past summer.

“This course was definitely a career-changing experience – I was able to work with a variety of infectious diseases and learn techniques that were not available for the parasite I work on.”

What’s Next

Beatrice is interested in staying in drug discovery for infectious diseases and currently looking at positions in both academia and industry.

 

Support trainees like Beatrice Colon. Give TODAY!